SCHEMBL10263176

SCHEMBL10263176

Cc1cc(NC(=O)Nc2cccc(C(=O)c3c[nH]c4ncccc34)c2)no1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
LMNA P02545 2/20 0.49
MAPK1 P28482 1/20 0.49
NEK2 P51955 2/20 0.49
RAB9A P51151 4/20 0.47
BRAF P15056 2/20 0.47
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
BRD4 O60885 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAP2K1 Q02750 1/20 0.43
HSD17B10 Q99714 1/20 0.43
BTK Q06187 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411211 0.86 KMT2A (0.50) ALDH1A1MEN1KMT2ANEK2RAB9A
SCHEMBL415961 0.86 BRAF (0.53) ALDH1A1KMT2ANEK2BRAFSMN1; SMN2
SCHEMBL413816 0.86 NEK2 (0.46) ALDH1A1NEK2BRAFSMN1; SMN2L3MBTL1
SCHEMBL410657 0.85 BRAF (0.62) ALDH1A1KMT2ANEK2RAB9ABRAF
SCHEMBL414864 0.85 BRD4 (0.48) ALDH1A1MEN1KMT2ANEK2RAB9A
SCHEMBL411058 0.85 NEK2 (0.53) ALDH1A1MEN1KMT2ANEK2RAB9A
SCHEMBL8252265 0.83 NEK2 (0.51) ALDH1A1MEN1KMT2ANEK2RAB9A
SCHEMBL410517 0.83 ALDH1A1 (0.59) ALDH1A1MEN1KMT2ALMNANEK2
SCHEMBL415660 0.83 NEK2 (0.51) ALDH1A1MEN1KMT2ALMNANEK2
SCHEMBL411788 0.82 DDX3X (0.53) ALDH1A1MEN1KMT2ALMNANEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-01-26 US disclosed
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 ALDH1A1 4348/4885MEN1 1452/4885KMT2A 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.